---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-035173"
form_type: "8-K"
ticker: "OGN"
cik: "0001821825"
company_name: "Organon & Co."
filed_at: "2025-04-15T23:59:59+00:00"
generated_at: "2026-05-23T14:53:07.403956+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Organon appoints Ramona A. Sequeira to Board of Directors

## Summary
- Appointment effective July 1, 2025; Board expands to 12 directors.
- Sequeira will serve on the Talent Committee of the Board.
- She is President of Global Portfolio Division at Takeda with 30+ years pharma experience.
- No related-party transactions or family relationships disclosed.
- Standard non-employee director compensation applies; indemnification agreement to be entered.

## SEC filing metadata
- accession: 0001104659-25-035173
- form_type: 8-K
- ticker: OGN
- cik: 0001821825
- company_name: Organon & Co.
- filed_at: 2025-04-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821825/000110465925035173/0001104659-25-035173-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821825/000110465925035173/tm2512324d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-035173
- JSON: https://secwatch.observer/filing/0001104659-25-035173.json
- Plain text: https://secwatch.observer/filing/0001104659-25-035173.txt

## Key facts
- Executive change
  Ramona A. Sequeira was appointed as Director at Organon & Co..
  - Action: appointed
  - Role: Director
  source text: the appointment of Ramona A. Sequeira will become immediately effective to fill the resulting vacancy.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821825/000110465925035173/0001104659-25-035173-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.